- Main navigation
- CLIC & The CTSA Program
- News & Events
- Groups
- Common Metrics Initiative
- Education & Career Development
- Team Science & Collaboration
- Resources
- CTSA Program Projects & Initiatives
- Contact
- Search
Mike's Blog can be found every month in the Ansible, the CTSA Program newsletter. Want to receive Mike's Blog in your inbox every month? Subscribe to the Ansible.
By: Audie Atienza, Ph.D., NCATS Program Officer; Sanae ElShourbagy Ferreira, Ph.D., NCATS Health Specialist; and Michael G. Kurilla, M.D., Ph.D., NCATS Director of the Division of Clinical Innovation While SARS-CoV-2 has demonstrated remarkable tenacity in terms of successfully navigating pharmaceutical as well as non-pharmaceutical interventions with waves of new variants throughout this pandemic
First a bit on COVID, then a small request. COVID will surely provide a wealth of material for future Monday morning armchair quarterbacking. One aspect (among many) of the overall public health response that has received harsh and severe criticism has been the approach, style, and substance of communications with the general public. From the WHO’s early tagline of ‘we have no evidence’ to the
A publication in Science Translational Medicine from last month, ‘Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States’ is noteworthy for several highlights. Beyond the science of the article itself, the fact that this work represents the efforts of two CTSAs (University of Alabama at Birmingham Center for Clinical and Translational Science
Public health now has a 3rd arrow in its quiver in the form of another COVID vaccine. The J&J vaccine is the first to offer a single dose with refrigeration requirements suitable for a wider array of health care settings. All that said, vaccine hesitancy remains an obstacle to an effective public health response. In this regard, CTSAs are playing a critical role in addressing public concerns about
The CTSA Program strives to deliver scientific and system changes that solve the many outstanding problems limiting the efficiency, effectiveness, and reach of clinical translational research, and thus get more treatments to more patients more quickly across the country. As the largest clinical translational science network and as an exemplar to team science, NCATS envisions the CTSA Program
We have arrived in 2021, hopeful for scientific advances to curb this pandemic once and for all. Our preparedness and readiness have been crucial in the development and implementation of several clinical trials leading the way in identifying safe and effective therapies and diagnostics for COVID-19. During this process we have witnessed incredible levels of innovation and adaptation, from the N3C
We have now completed a full cycle of virtual CTSA Program meetings where we had the opportunity to share each other’s presence – from a healthy and safe distance. Remarkably, during such a challenging year, we have managed to remain engaged and maintain quality and participation in our meetings under these “new normal” virtual gatherings. Summarizing a meeting with so many highlights is no easy
As COVID-19 continues as a top priority at all levels of our research enterprise, finding strategies to contain the spread of the virus and better treat the disease and its complications remains paramount. RADx-UP is an NIH initiative to support the development of community-engaged projects across the United States to assess and expand COVID-19 testing for underserved and/or vulnerable populations
As fall begins and with multiple promising treatment approaches to improve outcomes in COVID-19 coming to light, it is of critical need to rapidly implement trials to further study and confirm (or reject) these preliminary findings through well-designed randomized controlled clinical trials. As such, the resources, infrastructure and expertise throughout the CTSA consortium – including our Trial